On the contrary, the proportion of p53 overexpression in proximal colon cancer patients is lower than that in distal colon cancer, and the chemotherapy effect of oxaliplatin is better in CRC with p53 overexpression, so proximal colon cancer patients benefit less from oxaliplatin-based chemotherapy regimens129. The gene discussed is TP53; the disease is colorectal carcinoma.